Silver Book Fact

In one study, despite a 4-fold increase in prescription drug spending, overall health spending for Alzheimer’s patients undergoing drug therapy went down by 1/3.

Hill, Jerrold W., Robert Futterman, Vera Mastey, and Howard Fillit. The Effect of Donepezil Therapy on Health Costs in a Medicare Managed Care Plan. Managed Care Interface. 2002; 15(3): 63-70. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=11925682&dopt=AbstractPlus

Reference

Title
The Effect of Donepezil Therapy on Health Costs in a Medicare Managed Care Plan
Publication
Managed Care Interface
Publication Date
2002
Authors
Hill, Jerrold W., Robert Futterman, Vera Mastey, and Howard Fillit
Volume & Issue
Volume 15, Issue 3
Pages
63-70
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Valuing a QALY at $175,000, new drugs that would produce a 5-year delay in Alzheimer’s disease onset for all new cases between 2010 and 2050 would yield a benefit of…  
  • Some studies have indicate that the management of high cholesterol, type 2 diabetes, high blood pressure, overweight or obesity, and other cardiovascular risk factors may help avoid or delay cognitive…  
  • It is imperative to weigh costs of implementing new technologies for predicting onset of Alzheimer’s disease through biomarkers and delaying onset earlier against the potential benefits of improving health. Overall…  
  • According to one Parkinson’s expert, a 10% slowing of Parkinson’s disease progression would save $327 million per year.  
  • A new study reports that using optogenetics, stimulating specific brain cells using light, may provide better results for Parkinson’s patients than traditional deep brain stimulation because of the ability to…